Skip to main content
Erschienen in: BioDrugs 6/2014

01.12.2014 | Review Article

The Role of Interleukin-17A in Psoriatic Disease

verfasst von: Silvano Adami, Andrea Cavani, Francesco Rossi, Giampiero Girolomoni

Erschienen in: BioDrugs | Ausgabe 6/2014

Einloggen, um Zugang zu erhalten

Abstract

The pathogenic mechanisms of specific immune-mediated inflammatory diseases (IMIDs) are not fully understood, but are thought to involve activated T cells with the release of pro-inflammatory cytokines. Understanding the autoimmune inflammatory pathways has led to the development of biological agents that target specific components of effector immune mechanisms. Despite the availability of many effective drugs, a large proportion of patients with moderate to severe IMID do not receive adequate treatment, and many therapies show decreased efficacy over time. Therefore, there is a need for new therapies. One subset of T helper cells, Th17, and the cytokine interleukin-17 (IL-17) play a central role in the pathophysiology of autoimmune diseases such as psoriasis. IL-17 is involved in the modulation of pro-inflammatory cytokines, haematopoietic growth factors, antimicrobial peptides, chemokines, and molecules involved in tissue remodelling; the inflammatory cascades triggered by Th17 cells and IL-17 itself, when unregulated, can result in widespread inflammation-related damage. Evidence of increased Th17 activity and high levels of IL-17 has been found in psoriasis, as well as other inflammatory conditions, thereby signalling the potential utility of IL-17 as a therapeutic target. Clinical trials investigating IL-17 inhibitors, such as secukinumab, in patients with psoriatic disease have reported no significant safety concerns so far. It is hoped that these agents will improve the long-term prognosis of patients with these debilitating disorders.
Literatur
1.
Zurück zum Zitat Firestein GS, Corr M. Common mechanisms in immune-mediated inflammatory disease. J Rheumatol Suppl. 2005;73:8–13; discussion 29–30. Firestein GS, Corr M. Common mechanisms in immune-mediated inflammatory disease. J Rheumatol Suppl. 2005;73:8–13; discussion 29–30.
4.
Zurück zum Zitat Ortega C, Fernandez AS, Carrillo JM, Romero P, Molina IJ, Moreno JC, et al. IL-17-producing CD8+ T lymphocytes from psoriasis skin plaques are cytotoxic effector cells that secrete Th17-related cytokines. J Leukoc Biol. 2009;86(2):435–43. doi:10.1189/JLB.0109046.PubMedCrossRef Ortega C, Fernandez AS, Carrillo JM, Romero P, Molina IJ, Moreno JC, et al. IL-17-producing CD8+ T lymphocytes from psoriasis skin plaques are cytotoxic effector cells that secrete Th17-related cytokines. J Leukoc Biol. 2009;86(2):435–43. doi:10.​1189/​JLB.​0109046.PubMedCrossRef
6.
7.
Zurück zum Zitat Kuenzli S, Saurat JH. Retinoids for the treatment of psoriasis: outlook for the future. Curr Opin Investig Drugs. 2001;2(5):625–30.PubMed Kuenzli S, Saurat JH. Retinoids for the treatment of psoriasis: outlook for the future. Curr Opin Investig Drugs. 2001;2(5):625–30.PubMed
8.
Zurück zum Zitat Kunz M. Current treatment of psoriasis with biologics. Curr Drug Discov Technol. 2009;6(4):231–40.PubMedCrossRef Kunz M. Current treatment of psoriasis with biologics. Curr Drug Discov Technol. 2009;6(4):231–40.PubMedCrossRef
9.
Zurück zum Zitat Clark CM, Kirby B, Morris AD, Davison S, Zaki I, Emerson R, et al. Combination treatment with methotrexate and cyclosporin for severe recalcitrant psoriasis. Br J Dermatol. 1999;141(2):279–82.PubMedCrossRef Clark CM, Kirby B, Morris AD, Davison S, Zaki I, Emerson R, et al. Combination treatment with methotrexate and cyclosporin for severe recalcitrant psoriasis. Br J Dermatol. 1999;141(2):279–82.PubMedCrossRef
10.
Zurück zum Zitat Kuijpers AL, van de Kerkhof PC. Risk-benefit assessment of methotrexate in the treatment of severe psoriasis. Am J Clin Dermatol. 2000;1(1):27–39.PubMedCrossRef Kuijpers AL, van de Kerkhof PC. Risk-benefit assessment of methotrexate in the treatment of severe psoriasis. Am J Clin Dermatol. 2000;1(1):27–39.PubMedCrossRef
15.
Zurück zum Zitat Hueber W, Patel DD, Dryja T, Wright AM, Koroleva I, Bruin G et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med. 2010;2(52):52ra72. doi:10.1126/scitranslmed.3001107. Hueber W, Patel DD, Dryja T, Wright AM, Koroleva I, Bruin G et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med. 2010;2(52):52ra72. doi:10.​1126/​scitranslmed.​3001107.
20.
Zurück zum Zitat Ma HL, Liang S, Li J, Napierata L, Brown T, Benoit S, et al. IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation. J Clin Invest. 2008;118(2):597–607. doi:10.1172/JCI33263.PubMedCentralPubMed Ma HL, Liang S, Li J, Napierata L, Brown T, Benoit S, et al. IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation. J Clin Invest. 2008;118(2):597–607. doi:10.​1172/​JCI33263.PubMedCentralPubMed
21.
Zurück zum Zitat Rosmarin D, Strober BE. The potential of interleukin 12 inhibition in the treatment of psoriasis. J Drugs Dermatol. 2005;4(3):318–25.PubMed Rosmarin D, Strober BE. The potential of interleukin 12 inhibition in the treatment of psoriasis. J Drugs Dermatol. 2005;4(3):318–25.PubMed
22.
Zurück zum Zitat Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol. 2011;65(1):137–74. doi:10.1016/j.jaad.2010.11.055.PubMedCrossRef Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol. 2011;65(1):137–74. doi:10.​1016/​j.​jaad.​2010.​11.​055.PubMedCrossRef
24.
Zurück zum Zitat Reich K, Signorovitch J, Ramakrishnan K, Yu AP, Wu EQ, Gupta SR, et al. Benefit-risk analysis of adalimumab versus methotrexate and placebo in the treatment of moderate to severe psoriasis: comparison of adverse event-free response days in the CHAMPION trial. J Am Acad Dermatol. 2010;63(6):1011–8. doi:10.1016/j.jaad.2009.12.029.PubMedCrossRef Reich K, Signorovitch J, Ramakrishnan K, Yu AP, Wu EQ, Gupta SR, et al. Benefit-risk analysis of adalimumab versus methotrexate and placebo in the treatment of moderate to severe psoriasis: comparison of adverse event-free response days in the CHAMPION trial. J Am Acad Dermatol. 2010;63(6):1011–8. doi:10.​1016/​j.​jaad.​2009.​12.​029.PubMedCrossRef
26.
Zurück zum Zitat Esposito M, Gisondi P, Cassano N, Ferrucci G, Del Giglio M, Loconsole F, et al. Survival rate of antitumour necrosis factor-alpha treatments for psoriasis in routine dermatological practice: a multicentre observational study. Br J Dermatol. 2013;169(3):666–72. doi:10.1111/bjd.12422.PubMedCrossRef Esposito M, Gisondi P, Cassano N, Ferrucci G, Del Giglio M, Loconsole F, et al. Survival rate of antitumour necrosis factor-alpha treatments for psoriasis in routine dermatological practice: a multicentre observational study. Br J Dermatol. 2013;169(3):666–72. doi:10.​1111/​bjd.​12422.PubMedCrossRef
27.
Zurück zum Zitat Le Saux N. Biologic response modifiers to decrease inflammation: focus on infection risks. Paediatr Child Health. 2012;17(3):147–54.PubMedCentralPubMed Le Saux N. Biologic response modifiers to decrease inflammation: focus on infection risks. Paediatr Child Health. 2012;17(3):147–54.PubMedCentralPubMed
28.
Zurück zum Zitat Imperato AK, Bingham CO 3rd, Abramson SB. Overview of benefit/risk of biological agents. Clin Exp Rheumatol. 2004;22(5 Suppl 35):S108–14.PubMed Imperato AK, Bingham CO 3rd, Abramson SB. Overview of benefit/risk of biological agents. Clin Exp Rheumatol. 2004;22(5 Suppl 35):S108–14.PubMed
29.
Zurück zum Zitat Menter A. The status of biologic therapies in the treatment of moderate to severe psoriasis. Cutis. 2009;84(4 Suppl):14–24.PubMed Menter A. The status of biologic therapies in the treatment of moderate to severe psoriasis. Cutis. 2009;84(4 Suppl):14–24.PubMed
32.
Zurück zum Zitat Strober B, Buonanno M, Clark JD, Kawabata T, Tan H, Wolk R, et al. Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment. Br J Dermatol. 2013. doi:10.1111/bjd.12517. Strober B, Buonanno M, Clark JD, Kawabata T, Tan H, Wolk R, et al. Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment. Br J Dermatol. 2013. doi:10.​1111/​bjd.​12517.
33.
Zurück zum Zitat Papp KA, Menter A, Strober B, Langley RG, Buonanno M, Wolk R, et al. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a phase 2b randomized placebo-controlled dose-ranging study. Br J Dermatol. 2012;167(3):668–77. doi:10.1111/j.1365-2133.2012.11168.x.PubMedCrossRef Papp KA, Menter A, Strober B, Langley RG, Buonanno M, Wolk R, et al. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a phase 2b randomized placebo-controlled dose-ranging study. Br J Dermatol. 2012;167(3):668–77. doi:10.​1111/​j.​1365-2133.​2012.​11168.​x.PubMedCrossRef
34.
Zurück zum Zitat Leonardi C, Matheson R, Zachariae C, Cameron G, Li L, Edson-Heredia E, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med. 2012;366(13):1190–9. doi:10.1056/NEJMoa1109997.PubMedCrossRef Leonardi C, Matheson R, Zachariae C, Cameron G, Li L, Edson-Heredia E, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med. 2012;366(13):1190–9. doi:10.​1056/​NEJMoa1109997.PubMedCrossRef
35.
36.
Zurück zum Zitat Papp KA, Langley RG, Sigurgeirsson B, Abe M, Baker DR, Konno P, et al. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. Br J Dermatol. 2013;168(2):412–21. doi:10.1111/bjd.12110.PubMedCrossRef Papp KA, Langley RG, Sigurgeirsson B, Abe M, Baker DR, Konno P, et al. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. Br J Dermatol. 2013;168(2):412–21. doi:10.​1111/​bjd.​12110.PubMedCrossRef
37.
Zurück zum Zitat Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58(5):826–50. doi:10.1016/j.jaad.2008.02.039.PubMedCrossRef Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58(5):826–50. doi:10.​1016/​j.​jaad.​2008.​02.​039.PubMedCrossRef
38.
Zurück zum Zitat Zeichner JA. A practical approach to screening psoriasis patients for therapy with biologic agents. J Clin Aesthet Dermatol. 2008;1(3):50–4. Zeichner JA. A practical approach to screening psoriasis patients for therapy with biologic agents. J Clin Aesthet Dermatol. 2008;1(3):50–4.
39.
Zurück zum Zitat Vincent FB, Morand EF, Murphy K, Mackay F, Mariette X, Marcelli C. Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann Rheum Dis. 2013;72(2):165–78. doi:10.1136/annrheumdis-2012-202545.PubMedCrossRef Vincent FB, Morand EF, Murphy K, Mackay F, Mariette X, Marcelli C. Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann Rheum Dis. 2013;72(2):165–78. doi:10.​1136/​annrheumdis-2012-202545.PubMedCrossRef
42.
Zurück zum Zitat Eyerich K, Pennino D, Scarponi C, Foerster S, Nasorri F, Behrendt H et al. IL-17 in atopic eczema: linking allergen-specific adaptive and microbial-triggered innate immune response. J Allergy Clin Immunol. 2009;123(1):59–66 e4. doi:10.1016/j.jaci.2008.10.031. Eyerich K, Pennino D, Scarponi C, Foerster S, Nasorri F, Behrendt H et al. IL-17 in atopic eczema: linking allergen-specific adaptive and microbial-triggered innate immune response. J Allergy Clin Immunol. 2009;123(1):59–66 e4. doi:10.​1016/​j.​jaci.​2008.​10.​031.
43.
Zurück zum Zitat Ye P, Rodriguez FH, Kanaly S, Stocking KL, Schurr J, Schwarzenberger P, et al. Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. J Exp Med. 2001;194(4):519–27.PubMedCentralPubMedCrossRef Ye P, Rodriguez FH, Kanaly S, Stocking KL, Schurr J, Schwarzenberger P, et al. Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. J Exp Med. 2001;194(4):519–27.PubMedCentralPubMedCrossRef
45.
Zurück zum Zitat Parachuru VP, Coates DE, Milne TJ, Hussaini HM, Rich AM, Seymour GJ. Forkhead box P3-positive regulatory T-cells and interleukin 17-positive T-helper 17 cells in chronic inflammatory periodontal disease. J Periodontal Res. 2014. doi:10.1111/jre.12169.PubMed Parachuru VP, Coates DE, Milne TJ, Hussaini HM, Rich AM, Seymour GJ. Forkhead box P3-positive regulatory T-cells and interleukin 17-positive T-helper 17 cells in chronic inflammatory periodontal disease. J Periodontal Res. 2014. doi:10.​1111/​jre.​12169.PubMed
46.
Zurück zum Zitat Corneth OB, Mus AM, Asmawidjaja PS, Klein Wolterink RG, van Nimwegen M, Brem MD et al. Absence of interleukin-17 receptor A signaling prevents autoimmune inflammation of the joint and leads to a Th2-like phenotype in collagen-induced arthritis. Arthritis Rheumatol. 2014;66(2):340–9. doi:10.1002/art.38229. Corneth OB, Mus AM, Asmawidjaja PS, Klein Wolterink RG, van Nimwegen M, Brem MD et al. Absence of interleukin-17 receptor A signaling prevents autoimmune inflammation of the joint and leads to a Th2-like phenotype in collagen-induced arthritis. Arthritis Rheumatol. 2014;66(2):340–9. doi:10.​1002/​art.​38229.
47.
Zurück zum Zitat Pennino D, Eyerich K, Scarponi C, Carbone T, Eyerich S, Nasorri F, et al. IL-17 amplifies human contact hypersensitivity by licensing hapten nonspecific Th1 cells to kill autologous keratinocytes. J Immunol. 2010;184(9):4880–8. doi:10.4049/jimmunol.0901767.PubMedCrossRef Pennino D, Eyerich K, Scarponi C, Carbone T, Eyerich S, Nasorri F, et al. IL-17 amplifies human contact hypersensitivity by licensing hapten nonspecific Th1 cells to kill autologous keratinocytes. J Immunol. 2010;184(9):4880–8. doi:10.​4049/​jimmunol.​0901767.PubMedCrossRef
50.
Zurück zum Zitat Ichiyama K, Yoshida H, Wakabayashi Y, Chinen T, Saeki K, Nakaya M, et al. Foxp3 inhibits RORgammat-mediated IL-17A mRNA transcription through direct interaction with RORgammat. J Biol Chem. 2008;283(25):17003–8. doi:10.1074/jbc.M801286200.PubMedCrossRef Ichiyama K, Yoshida H, Wakabayashi Y, Chinen T, Saeki K, Nakaya M, et al. Foxp3 inhibits RORgammat-mediated IL-17A mRNA transcription through direct interaction with RORgammat. J Biol Chem. 2008;283(25):17003–8. doi:10.​1074/​jbc.​M801286200.PubMedCrossRef
62.
Zurück zum Zitat Steiner GE, Newman ME, Paikl D, Stix U, Memaran-Dagda N, Lee C, et al. Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate. Prostate. 2003;56(3):171–82. doi:10.1002/pros.10238.PubMedCrossRef Steiner GE, Newman ME, Paikl D, Stix U, Memaran-Dagda N, Lee C, et al. Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate. Prostate. 2003;56(3):171–82. doi:10.​1002/​pros.​10238.PubMedCrossRef
63.
Zurück zum Zitat Albanesi C, Scarponi C, Cavani A, Federici M, Nasorri F, Girolomoni G. Interleukin-17 is produced by both Th1 and Th2 lymphocytes, and modulates interferon-gamma- and interleukin-4-induced activation of human keratinocytes. J Invest Dermatol. 2000;115(1):81–7. doi:10.1046/j.1523-1747.2000.00041.x.PubMedCrossRef Albanesi C, Scarponi C, Cavani A, Federici M, Nasorri F, Girolomoni G. Interleukin-17 is produced by both Th1 and Th2 lymphocytes, and modulates interferon-gamma- and interleukin-4-induced activation of human keratinocytes. J Invest Dermatol. 2000;115(1):81–7. doi:10.​1046/​j.​1523-1747.​2000.​00041.​x.PubMedCrossRef
66.
Zurück zum Zitat Kehlen A, Thiele K, Riemann D, Langner J. Expression, modulation and signalling of IL-17 receptor in fibroblast-like synoviocytes of patients with rheumatoid arthritis. Clin Exp Immunol. 2002;127(3):539–46.PubMedCentralPubMedCrossRef Kehlen A, Thiele K, Riemann D, Langner J. Expression, modulation and signalling of IL-17 receptor in fibroblast-like synoviocytes of patients with rheumatoid arthritis. Clin Exp Immunol. 2002;127(3):539–46.PubMedCentralPubMedCrossRef
67.
Zurück zum Zitat Cho ML, Kang JW, Moon YM, Nam HJ, Jhun JY, Heo SB, et al. STAT3 and NF-kappaB signal pathway is required for IL-23-mediated IL-17 production in spontaneous arthritis animal model IL-1 receptor antagonist-deficient mice. J Immunol. 2006;176(9):5652–61.PubMedCrossRef Cho ML, Kang JW, Moon YM, Nam HJ, Jhun JY, Heo SB, et al. STAT3 and NF-kappaB signal pathway is required for IL-23-mediated IL-17 production in spontaneous arthritis animal model IL-1 receptor antagonist-deficient mice. J Immunol. 2006;176(9):5652–61.PubMedCrossRef
68.
Zurück zum Zitat Patel DN, King CA, Bailey SR, Holt JW, Venkatachalam K, Agrawal A, et al. Interleukin-17 stimulates C-reactive protein expression in hepatocytes and smooth muscle cells via p38 MAPK and ERK1/2-dependent NF-kappaB and C/EBPbeta activation. J Biol Chem. 2007;282(37):27229–38. doi:10.1074/jbc.M703250200.PubMedCrossRef Patel DN, King CA, Bailey SR, Holt JW, Venkatachalam K, Agrawal A, et al. Interleukin-17 stimulates C-reactive protein expression in hepatocytes and smooth muscle cells via p38 MAPK and ERK1/2-dependent NF-kappaB and C/EBPbeta activation. J Biol Chem. 2007;282(37):27229–38. doi:10.​1074/​jbc.​M703250200.PubMedCrossRef
72.
73.
Zurück zum Zitat Marzano AV, Tedeschi A, Polloni I, Crosti C, Cugno M. Interactions between inflammation and coagulation in autoimmune and immune-mediated skin diseases. Curr Vasc Pharmacol. 2012;10(5):647–52.PubMedCrossRef Marzano AV, Tedeschi A, Polloni I, Crosti C, Cugno M. Interactions between inflammation and coagulation in autoimmune and immune-mediated skin diseases. Curr Vasc Pharmacol. 2012;10(5):647–52.PubMedCrossRef
76.
77.
Zurück zum Zitat Albanesi C, Cavani A, Girolomoni G. IL-17 is produced by nickel-specific T lymphocytes and regulates ICAM-1 expression and chemokine production in human keratinocytes: synergistic or antagonist effects with IFN-gamma and TNF-alpha. J Immunol. 1999;162(1):494–502.PubMed Albanesi C, Cavani A, Girolomoni G. IL-17 is produced by nickel-specific T lymphocytes and regulates ICAM-1 expression and chemokine production in human keratinocytes: synergistic or antagonist effects with IFN-gamma and TNF-alpha. J Immunol. 1999;162(1):494–502.PubMed
80.
Zurück zum Zitat de Rooy DP, van der Linden MP, Knevel R, Huizinga TW, van der Helm-van Mil AH. Predicting arthritis outcomes—what can be learned from the Leiden Early Arthritis Clinic? Rheumatology (Oxford). 2011;50(1):93–100. doi:10.1093/rheumatology/keq230. de Rooy DP, van der Linden MP, Knevel R, Huizinga TW, van der Helm-van Mil AH. Predicting arthritis outcomes—what can be learned from the Leiden Early Arthritis Clinic? Rheumatology (Oxford). 2011;50(1):93–100. doi:10.​1093/​rheumatology/​keq230.
81.
82.
Zurück zum Zitat Kostenuik PJ, Shalhoub V. Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption. Curr Pharm Des. 2001;7(8):613–35.PubMedCrossRef Kostenuik PJ, Shalhoub V. Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption. Curr Pharm Des. 2001;7(8):613–35.PubMedCrossRef
84.
Zurück zum Zitat Stolina M, Adamu S, Ominsky M, Dwyer D, Asuncion F, Geng Z, et al. RANKL is a marker and mediator of local and systemic bone loss in two rat models of inflammatory arthritis. J Bone Miner Res. 2005;20(10):1756–65. doi:10.1359/JBMR.050601.PubMedCrossRef Stolina M, Adamu S, Ominsky M, Dwyer D, Asuncion F, Geng Z, et al. RANKL is a marker and mediator of local and systemic bone loss in two rat models of inflammatory arthritis. J Bone Miner Res. 2005;20(10):1756–65. doi:10.​1359/​JBMR.​050601.PubMedCrossRef
85.
Zurück zum Zitat Bellido T, Ali AA, Gubrij I, Plotkin LI, Fu Q, O’Brien CA, et al. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology. 2005;146(11):4577–83. doi:10.1210/en.2005-0239.PubMedCrossRef Bellido T, Ali AA, Gubrij I, Plotkin LI, Fu Q, O’Brien CA, et al. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology. 2005;146(11):4577–83. doi:10.​1210/​en.​2005-0239.PubMedCrossRef
86.
87.
Zurück zum Zitat Crotti TN, Smith MD, Weedon H, Ahern MJ, Findlay DM, Kraan M, et al. Receptor activator NF-kappaB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis. Ann Rheum Dis. 2002;61(12):1047–54.PubMedCentralPubMedCrossRef Crotti TN, Smith MD, Weedon H, Ahern MJ, Findlay DM, Kraan M, et al. Receptor activator NF-kappaB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis. Ann Rheum Dis. 2002;61(12):1047–54.PubMedCentralPubMedCrossRef
88.
Zurück zum Zitat Liu YY, Long L, Wang SY, Guo JP, Ye H, Cui LF, et al. Circulating Dickkopf-1 and osteoprotegerin in patients with early and longstanding rheumatoid arthritis. Chin Med J (Engl). 2010;123(11):1407–12.PubMed Liu YY, Long L, Wang SY, Guo JP, Ye H, Cui LF, et al. Circulating Dickkopf-1 and osteoprotegerin in patients with early and longstanding rheumatoid arthritis. Chin Med J (Engl). 2010;123(11):1407–12.PubMed
89.
Zurück zum Zitat Singh TP, Schon MP, Wallbrecht K, Michaelis K, Rinner B, Mayer G, et al. 8-Methoxypsoralen plus ultraviolet A therapy acts via inhibition of the IL-23/Th17 axis and induction of Foxp3+ regulatory T cells involving CTLA4 signaling in a psoriasis-like skin disorder. J Immunol. 2010;184(12):7257–67. doi:10.4049/jimmunol.0903719.PubMedCrossRef Singh TP, Schon MP, Wallbrecht K, Michaelis K, Rinner B, Mayer G, et al. 8-Methoxypsoralen plus ultraviolet A therapy acts via inhibition of the IL-23/Th17 axis and induction of Foxp3+ regulatory T cells involving CTLA4 signaling in a psoriasis-like skin disorder. J Immunol. 2010;184(12):7257–67. doi:10.​4049/​jimmunol.​0903719.PubMedCrossRef
92.
Zurück zum Zitat Rich P, Sigurgeirsson B, Thaci D, Ortonne JP, Paul C, Schopf RE, et al. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study. Br J Dermatol. 2013;168(2):402–11. doi:10.1111/bjd.12112.PubMedCrossRef Rich P, Sigurgeirsson B, Thaci D, Ortonne JP, Paul C, Schopf RE, et al. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study. Br J Dermatol. 2013;168(2):402–11. doi:10.​1111/​bjd.​12112.PubMedCrossRef
93.
Zurück zum Zitat Genovese MC, Durez P, Richards HB, Supronik J, Dokoupilova E, Mazurov V, et al. Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study. Ann Rheum Dis. 2013;72(6):863–9. doi:10.1136/annrheumdis-2012-201601.PubMedCrossRef Genovese MC, Durez P, Richards HB, Supronik J, Dokoupilova E, Mazurov V, et al. Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study. Ann Rheum Dis. 2013;72(6):863–9. doi:10.​1136/​annrheumdis-2012-201601.PubMedCrossRef
95.
Zurück zum Zitat McInnes IB, Sieper J, Braun J, Emery P, van der Heijde D, Isaacs JD, et al. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. Ann Rheum Dis. 2013. doi:10.1136/annrheumdis-2012-202646. McInnes IB, Sieper J, Braun J, Emery P, van der Heijde D, Isaacs JD, et al. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. Ann Rheum Dis. 2013. doi:10.​1136/​annrheumdis-2012-202646.
96.
Zurück zum Zitat Dick AD, Tugal-Tutkun I, Foster S, Zierhut M, Melissa Liew SH, Bezlyak V et al. Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. Ophthalmology. 2013;120(4):777–87. doi:10.1016/j.ophtha.2012.09.040. Dick AD, Tugal-Tutkun I, Foster S, Zierhut M, Melissa Liew SH, Bezlyak V et al. Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. Ophthalmology. 2013;120(4):777–87. doi:10.​1016/​j.​ophtha.​2012.​09.​040.
97.
Zurück zum Zitat Rich P, Sigurgeirsson B, Thaci DP, Ortonne JP, Paul C, Schopf RE, et al. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomised, double-blind, placebo-controlled, phase II regimen-finding study. Br J Dermatol. 2012. doi:10.1111/bjd.12070.PubMed Rich P, Sigurgeirsson B, Thaci DP, Ortonne JP, Paul C, Schopf RE, et al. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomised, double-blind, placebo-controlled, phase II regimen-finding study. Br J Dermatol. 2012. doi:10.​1111/​bjd.​12070.PubMed
98.
Zurück zum Zitat Hueber W, Sands BE, Lewitzky S, Vandemeulebroecke M, Reinisch W, Higgins PD, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012;61(12):1693–700. doi:10.1136/gutjnl-2011-301668.PubMedCrossRef Hueber W, Sands BE, Lewitzky S, Vandemeulebroecke M, Reinisch W, Higgins PD, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012;61(12):1693–700. doi:10.​1136/​gutjnl-2011-301668.PubMedCrossRef
100.
Zurück zum Zitat Meyer MW, Zachariae C, Bendtzen K, Skov L. Lack of anti-drug antibodies in patients with psoriasis well-controlled on long-term treatment with tumour necrosis factor inhibitors. Acta Derm Venereol. 2012;92(4):362–4. doi:10.2340/00015555-1376.PubMedCrossRef Meyer MW, Zachariae C, Bendtzen K, Skov L. Lack of anti-drug antibodies in patients with psoriasis well-controlled on long-term treatment with tumour necrosis factor inhibitors. Acta Derm Venereol. 2012;92(4):362–4. doi:10.​2340/​00015555-1376.PubMedCrossRef
101.
102.
Zurück zum Zitat Busse WW, Holgate S, Kerwin E, Chon Y, Feng J, Lin J, et al. Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma. Am J Respir Crit Care Med. 2013;188(11):1294–302. doi:10.1164/rccm.201212-2318OC.PubMedCrossRef Busse WW, Holgate S, Kerwin E, Chon Y, Feng J, Lin J, et al. Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma. Am J Respir Crit Care Med. 2013;188(11):1294–302. doi:10.​1164/​rccm.​201212-2318OC.PubMedCrossRef
Metadaten
Titel
The Role of Interleukin-17A in Psoriatic Disease
verfasst von
Silvano Adami
Andrea Cavani
Francesco Rossi
Giampiero Girolomoni
Publikationsdatum
01.12.2014
Verlag
Springer International Publishing
Erschienen in
BioDrugs / Ausgabe 6/2014
Print ISSN: 1173-8804
Elektronische ISSN: 1179-190X
DOI
https://doi.org/10.1007/s40259-014-0098-x

Weitere Artikel der Ausgabe 6/2014

BioDrugs 6/2014 Zur Ausgabe

Acknowledgement to Referees

Acknowledgement to Referees